Skip to main content

Zoetis Inc. guidance

  • ZTS · NYSE
  • Pharmaceuticals
  • S&P 500
$83.82+1.04%Close 13 Nov 2026

In its results release of 5 Nov 2026 (Q3 FY2026), Zoetis Inc. gave 3 forecasts in figures, among them EPS (adjusted) of $6.25 to $6.35 for FY2026. Over the last two years, results landed above the company's own last range 0 of 3 times, within it 3 and below it 0.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 5 Nov 2026

MeasurePeriodGuidanceAs stated
EPS · Adjusted · RaisedFY2026$6.25 to $6.35Raised adjusted diluted EPS to a range of $6.25 to $6.35
EPSFY2026$5.50 to $5.60Reported diluted EPS $5.50 to $5.60
Tax rateFY202620%Effective tax rate on adjusted income 20%

Source: the company's earnings release.

Guidance against results above 0 · within 3 · below 0

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
RevenueFY2026$9.68B to $9.96BLowered once—To come
EPSFY2026$5.50 to $5.60Lowered 3 times—To come
EPS · AdjustedFY2026$6.25 to $6.35Raised once, lowered twice—To come
Net income · AdjustedFY2026$2.87B to $2.95BLowered once—To come
Tax rateFY202620%Lowered once—To come
RevenueFY2025$9.40B to $9.47BRaised twice, lowered once$9.47BWithin the range
Tax rateFY202520.5%Lowered once20.45%Within the range
RevenueFY2024$9.20B to $9.30BGiven once$9.26BWithin the range

ZTS in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.